Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic cancer.
Oblique Therapeutics has raised $1.4M in total funding. The most recent round was Undisclosed. The last funding was announced in June 2026.
Oblique Therapeutics's investors include Almi Invest.
Oblique Therapeutics is headquartered in Göteborg, Sweden.
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic cancer.
Oblique Therapeutics is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oblique Therapeutics — Funding & Investors." VCBacked, June 30, 2026, https://www.vcbacked.co/company/oblique-therapeutics. Accessed November 15, 2026.
VCBacked. (2026). Oblique Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/oblique-therapeutics
{{cite web |title=Oblique Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/oblique-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Oblique Therapeutics? Request a listing update